DOCSLIB.ORG

Lnc-EPCAM and Lnc-BHLHE41 AS RNA REGULATORS of BREAST CANCER and BREAST CANCER PREVENTION

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lnc-EPCAM and Lnc-BHLHE41 AS RNA REGULATORS of BREAST CANCER and BREAST CANCER PREVENTION Lnc-EPCAM AND Lnc-BHLHE41 AS RNA REGULATORS OF BREAST CANCER AND BREAST CANCER PREVENTION A Dissertation Submitted to the Temple University Graduate School Board In Partial Fulfillment of the Requirements for the Degree DOCTOR OF PHILOSOPHY By MARIA BARTON May 2017 Examining Committee Members: Jose Russo, MD, FACP, Advisor, The Irma H. Russo MD Breast Cancer Research Laboratory, Fox Chase Cancer Center Dianne Soprano, PhD, Advisor, Department of Biochemistry, Lewis Katz School of Medicine, Temple University Ana Gamero, PhD, Department of Biochemistry, Lewis Katz School of Medicine, Temple University Nora Engel, PhD, Department of Cancer Biology, Genetics and Epigenetics, Fels Institute, Lewis Katz School of Medicine, Temple University Richard Katz, PhD, External Member, Department of Epigenetics, Fox Chase Cancer Center Raghbir Athwal, PhD, External Member, Department of Pathology and Laboratory Medicine, Fels Institute, Lewis Katz School of Medicine, Temple University © Copyright 2016 By MARIA BARTON All Rights Reserved ii ABSTRACT The objective of this study was to unveil a novel area of gene regulation in breast cancer and breast cancer prevention through the study of a recent discovered class of genetic regulators named long non-coding RNAs (lncRNAs). LncRNAs are RNA molecules longer than 200 nucleotides that are not translated into proteins, but regulate the transcription of genes involved in different cellular processes, including differentiation, cancer initiation and progression. The link between lncRNAs and cancer is well documented in the literature. More recently, their relevance in the transcription field is beginning to be explored and their roles have been found to vary from guiding proteins to the genome to scaffolding proteins complexes needed for the transcription of a specific gene. Initial transcriptome analysis of normal breast of parous and nulliparous postmenopausal women revealed that several lncRNAs are differentially expressed in the parous breast. This observation provided evidence of a potential role of lncRNAs in the regulation of transcription and their function in pregnancy’s preventive effect in reducing the lifetime risk of developing breast cancer. Specifically, RNA sequencing of healthy postmenopausal breast tissue biopsies from eight parous and eight nulliparous women using Illumina platform was performed. The sequencing results showed that there are 42 lncRNAs differentially expressed between parous and nulliparous breast tissue. These data led to the hypothesis that these novel lncRNAs may be drivers in the process of development that occurs in the mammary gland during pregnancy, providing protection against breast cancer. After analysis of these 42 lncRNAs using bioinformatics tools, review of the scientific literature, and real-time PCR analysis, two lncRNAs (lncBHLHE41 and lncEPCAM) were selected to be tested in vitro, using different molecular techniques in human epithelial breast cell lines to determine their relevance in breast cancer. This project provided novel information on lncRNAs induced by pregnancy in the breast tissue, and identified two lncRNAs as potential key regulators in breast differentiation and cancer progression. The manipulation of these lncRNAs led to evidence of their function in vitro and, using xenograft studies, we determined their relevance in vivo. Although treatment for cancer using lncRNAs as targets is in its infancy at the clinic, the advancement in knowledge and technology to study their relevance in disease could lead to the development of therapeutics for breast cancer and breast cancer prevention in the near future. iii To my little “chinis” who has changed my life forever In memory of Miguel R. Barton iv ACKNOWLEDGEMENTS I feel this is the hardest part for me to write. I am so grateful to so many people who have contributed to me getting to this point. I first want to start by acknowledging my undergraduate mentor Dr. Sonia Rodriguez who sprinkled on me her passion for research. The few years I was her mentoree, and had the pleasure of interacting with her diverse team, ignited the fire for research that now burns in me. I have been very lucky with the mentors I have had and that is why my Master’s Degree mentor Dr. Robert H. Silverman also deserves my gratitude for the achievements during my PhD. It was in his laboratory, a great experience at the Cleveland Clinic, that I learned how to start walking the path of becoming an independent researcher and melting into the challenging working environment of a research-based institution. That is why, when I met Dr. Russo at Fox Chase Cancer Center, I already felt at home. Dr. Russo was welcoming from the very beginning. That is just who he is. Although I was nervous thinking of the responsibilities ahead of me, I felt comfortable during our first encounter, which feels like yesterday. Thank you for letting me (and even encouraging me) to always speak my mind. I owe you a great deal of my achievements and I will be forever grateful for the opportunity of working in The Irma H. Russo MD Breast Cancer Research Laboratory. In addition to my mentors, I want to deeply thank my advisory committee, Dr. Dianne Soprano, Dr. Nora Engel and Dr. Ana Gamero for their continuous support and suggestions at every step during my graduate work. I took your comments into action and your input undoubtedly gave shape to this very challenging project. Thank you all for your caring guidance and advice. To my external dissertation readers, Dr. Richard A. Katz and the generous Dr. Raghbir Athwal, it has been a pleasure meeting you both. I am so grateful to all the faculty, postdoctoral fellows and graduate students at Fox Chase Cancer Center for their availability and cooperative work ethics and Dr. Katz is a true embodiment of the institution’s values and mission. As I said, Fox Chase felt like home on my first visit, and time didn’t prove me wrong. Another “home” away from home was Fels Institute. I am very grateful to my outside research proposal sponsor, Dr. Xavier Grana, not only for his invaluable contributions and guidance during my ORP project but also for taking me under the CBGN wing. I felt I had the best of two worlds being a Biochemistry student in a Cell, Molecular, Genetics and Epigenetics cluster. v To my past and present lab members, I wouldn’t have been able to do this without your suggestions, constructive criticism, and friendship. Julia, Su, Tom, Theresa, and Dr. Irma Russo helped me design and/or carry out experiments. In particular I want to thank Ricardo from the bottom of my heart for always being available (in the most broad way) to discuss results and future directions for this project. In the Russo lab, I was honored to mentor many undergraduate and graduate students and these experiences have shaped me into a more solid scientist. Special thanks to Dominic, Olivia and Tyler for reminding me how much I love teaching. To my graduate fellows in this great adventure, I want to thank Danielle Feather, Elsie Samakai, Umme Ayesa, and Jenny Shrestha for their words of support and encouragement at every step. I’m happy we will be finding the light at the end of the tunnel and wish you all success in your careers. Last but not least, I want to thank the drivers and energy fillers of my life. To the love of my life, Javier, and the little princess we added to the family, my beloved Zoe. Javier, your determination to be the best professional you possibly can have always inspired me to find the best scientist in me. I’m so proud of our “all-terrain” family. To my sisters, Victoria and Luciana, my beautiful niece Sofia and especially my mother Susana. Mom, you have been my utmost supporter, several times flying overseas so that I could get to this point. Gracias. vi TABLE OF CONTENTS Page ABSTRACT ................................................................................................................... iii DEDICATION ………………………………………………………………………………..... iv ACKNOWLEDGEMENTS ............................................................................................... v LIST OF TABLES ………………………………………………………………………….….. x LIST OF FIGURES ………………………………………………………………………….… xi LIST OF ABBREVIATIONS ......................................................................................... xiv HYPOTHESIS ……………………………………………………………………………….. xvi SPECIFIC AIMS …………………………………………………………………………….. xvii CHAPTER 1: INTRODUCTION ...................................................................................... 1 1.1. Incidence and mortality rates in recent years ..............................................................2 1.2. Breast Cancer Subtypes ................................................................................................2 1.3. Breast Cancer Prevention ..............................................................................................3 1.4. Role of lncRNA in Development and Disease ...............................................................4 1.4.1. Molecular interactions and functional roles of lncRNA ...................................................... 6 1.4.1.i- Epigenetic Transcriptional Regulation .......................................................................... 7 1.4.1.ii - Enhancer-associated lncRNA ...................................................................................... 8 1.4.1.iii - mRNA Processing ....................................................................................................... 8 1.4.1.iv - miRNA Sequestration .................................................................................................
Load more

Recommended publications
  • Database of Cattle Candidate Genes and Genetic Markers for Milk Production and Mastitis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central doi:10.1111/j.1365-2052.2009.01921.x Database of cattle candidate genes and genetic markers for milk production and mastitis J. Ogorevc*, T. Kunej*, A. Razpet and P. Dovc Department of Animal Science, Biotechnical Faculty, University of Ljubljana, Domzale, Slovenia Summary A cattle database of candidate genes and genetic markers for milk production and mastitis has been developed to provide an integrated research tool incorporating different types of information supporting a genomic approach to study lactation, udder development and health. The database contains 943 genes and genetic markers involved in mammary gland development and function, representing candidates for further functional studies. The candidate loci were drawn on a genetic map to reveal positional overlaps. For identification of candidate loci, data from seven different research approaches were exploited: (i) gene knockouts or transgenes in mice that result in specific phenotypes associated with mam- mary gland (143 loci); (ii) cattle QTL for milk production (344) and mastitis related traits (71); (iii) loci with sequence variations that show specific allele-phenotype interactions associated with milk production (24) or mastitis (10) in cattle; (iv) genes with expression profiles associated with milk production (207) or mastitis (107) in cattle or mouse; (v) cattle milk protein genes that exist in different genetic variants (9); (vi) miRNAs expressed in bovine mammary gland (32) and (vii) epigenetically regulated cattle genes associated with mammary gland function (1). Fourty-four genes found by multiple independent analyses were suggested as the most promising candidates and were further in silico analysed for expression levels in lactating mammary gland, genetic variability and top biological func- tions in functional networks.
    [Show full text]
  • Basic Helix-Loop-Helix Transcription Factors DEC1 and DEC2 Regulate the Paclitaxel-Induced Apoptotic Pathway of MCF-7 Human Breast Cancer Cells
    INTERNATIONAL JOURNAL OF MoleCular MEDICine 27: 491-495, 2011 Basic helix-loop-helix transcription factors DEC1 and DEC2 regulate the paclitaxel-induced apoptotic pathway of MCF-7 human breast cancer cells YUNYAN WU1,2, FUYUKI SATO1, UJJAL KUMAR BHAWAL3, TAKESHI KAWAMOTO4, KATSUMI FUJIMOTO4, MITSUHIDE NOSHIRO4, SATOKO MOROHASHI1, YUKIO KATO4 and HIROSHI KIJIMA1 1Department of Pathology and Bioscience, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, Japan; 2Department of Pathology, College of Basic Medical Sciences, China Medical University, Shenyang 110001, P.R. China; 3Department of Oral and Maxillofacial Surgery and High-Tech Research Center, Kanagawa Dental College, Yokosuka 238-8580; 4Department of Dental and Medical Biochemistry, Hiroshima University Graduate School of Biomedical Science, Hiroshima 734-8553, Japan Received November 17, 2010; Accepted January 10, 2011 DOI: 10.3892/ijmm.2011.617 Abstract. Differentiated embryonic chondrocyte gene Introduction (DEC) 1 (BHLHE40/Stra13/Sharp2) and DEC2 (BHLHE41/ Sharp1) are basic helix-loop-helix (bHLH) transcription Paclitaxel is an anti-tumor drug that is used against a wide factors that are associated with the regulation of apoptosis, cell variety of solid tumors (1,2) and affects the expression of proliferation and circadian rhythms, as well as malignancy Bcl-2, Bcl-xL and phosphorylated-c-Jun NH2-terminal kinase in various cancers. However, the roles of DEC1 and DEC2 (JNK), and the activation of caspases and poly (ADP-ribose) expression in breast cancer are poorly understood. In this polymerase PARP (3-6), resulting in the induction of apop- study, we sought to examine the roles of DEC1 and DEC2 tosis by p53-dependent or -independent mechanisms (7-9).
    [Show full text]
  • Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer Joshua W
    Published OnlineFirst September 21, 2018; DOI: 10.1158/0008-5472.CAN-18-0687 Cancer Priority Report Research Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer Joshua W. Russo1,CeGao2, Swati S. Bhasin2, Olga S. Voznesensky1, Carla Calagua3, Seiji Arai1,4, Peter S. Nelson5, Bruce Montgomery6, Elahe A. Mostaghel5, Eva Corey6, Mary-Ellen Taplin7, Huihui Ye3, Manoj Bhasin2, and Steven P. Balk1 Abstract The standard treatment for metastatic prostate cancer, cleaves dipeptides from multiple growth factors, resulting in androgen deprivation therapy (ADT), is designed to suppress their increased degradation. DPP4 mRNA and protein were androgen receptor (AR) activity. However, men invariably also decreased in clinical CRPC cases, and inhibition of progress to castration-resistant prostate cancer (CRPC), and DPP4 with sitagliptin enhanced the growth of prostate AR reactivation contributes to progression in most cases. To cancer xenografts following castration. Significantly, DPP4 identify mechanisms that may drive CRPC, we examined a inhibitors are frequently used to treat type 2 diabetes as they VCaP prostate cancer xenograft model as tumors progressed increase insulin secretion. Together, these results implicate from initial androgen sensitivity prior to castration to castra- DPP4 as an AR-regulated tumor suppressor gene whose tion resistance and then on to relapse after combined therapy loss enhances growth factor activity and suggest that treat- with further AR-targeted drugs (abiraterone plus enzaluta- ment with DPP4 inhibitors may accelerate emergence of mide). AR activity persisted in castration-resistant and abir- resistance to ADT. aterone/enzalutamide–resistant xenografts and was associated with increased expression of the AR gene and the AR-V7 splice Significance: These findings identify DPP4 as an AR-stim- variant.
    [Show full text]
  • The Title of the Dissertation
    UNIVERSITY OF CALIFORNIA SAN DIEGO Novel network-based integrated analyses of multi-omics data reveal new insights into CD8+ T cell differentiation and mouse embryogenesis A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Bioinformatics and Systems Biology by Kai Zhang Committee in charge: Professor Wei Wang, Chair Professor Pavel Arkadjevich Pevzner, Co-Chair Professor Vineet Bafna Professor Cornelis Murre Professor Bing Ren 2018 Copyright Kai Zhang, 2018 All rights reserved. The dissertation of Kai Zhang is approved, and it is accept- able in quality and form for publication on microfilm and electronically: Co-Chair Chair University of California San Diego 2018 iii EPIGRAPH The only true wisdom is in knowing you know nothing. —Socrates iv TABLE OF CONTENTS Signature Page ....................................... iii Epigraph ........................................... iv Table of Contents ...................................... v List of Figures ........................................ viii List of Tables ........................................ ix Acknowledgements ..................................... x Vita ............................................. xi Abstract of the Dissertation ................................. xii Chapter 1 General introduction ............................ 1 1.1 The applications of graph theory in bioinformatics ......... 1 1.2 Leveraging graphs to conduct integrated analyses .......... 4 1.3 References .............................. 6 Chapter 2 Systematic
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0186843 A1 ZHANG Et Al
    US 2014O186843A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0186843 A1 ZHANG et al. (43) Pub. Date: Jul. 3, 2014 (54) METHODS, SYSTEMS, AND APPARATUS FOR (22) Filed: Dec. 12, 2013 IDENTIFYING TARGET SEQUENCES FOR CAS ENZYMES OR CRISPR-CAS SYSTEMIS Related U.S. Application Data FORTARGET SEQUENCES AND (60) Provisional application No. 61/736,527, filed on Dec. CONVEYING RESULTS THEREOF 12, 2012, provisional application No. 61/748,427, filed on Jan. 2, 2013, provisional application No. (71) Applicants: Massachusetts Institute of Technology, 61/791,409, filed on Mar. 15, 2013, provisional appli Cambridge, MA (US): THE BROAD cation No. 61/835,931, filed on Jun. 17, 2013. INSTITUTE, INC., Cambridge, MA (US) Publication Classification (72) Inventors: Feng ZHANG, Cambridge, MA (US); (51) Int. C. Naomi HABIB, Cambridge, MA (US) CI2O I/68 (2006.01) (52) U.S. C. (73) Assignees: Massachusetts Institute of Technology, CPC ...................................... CI2O I/686 (2013.01) Cambridge, MA (US): THE BROAD USPC ....................................... 435/6.12: 435/287.2 INSTITUTE, INC., Cambridge, MA (US) (57) ABSTRACT Disclosed are locational or positional methods concerning (21) Appl. No.: 14/104,900 CRISPR-Cas systems, and apparatus therefor. Patent Application Publication Jul. 3, 2014 Sheet 1 of 50 US 2014/O186843 A1 s g:23:3:3: 83: FIG. 1 Patent Application Publication Jul. 3, 2014 Sheet 2 of 50 US 2014/O186843 A1 §§§§ §§§§§§ Patent Application Publication Jul. 3, 2014 Sheet 3 of 50 US 2014/O186843 A1 NLs SpCass GFP SpCass GFP NS NLS Spass GFP LS 8 N.S. tery RNase Sp RNase is Cerry NS FG.
    [Show full text]
  • Mechanistic Involvement of Long Non-Coding Rnas in Oncotherapeutics Resistance in Triple-Negative Breast Cancer
    cells Review Mechanistic Involvement of Long Non-Coding RNAs in Oncotherapeutics Resistance in Triple-Negative Breast Cancer Samarth Kansara 1, Vijay Pandey 2,3, Peter E. Lobie 2,3, Gautam Sethi 4,*, Manoj Garg 5 and Amit Kumar Pandey 1,* 1 Amity Institute of Biotechnology, Amity University Haryana, Panchgaon, Manesar, Haryana 122413, India; [email protected] 2 Tsinghua-Berkeley Shenzhen Institute, Tsinghua University, Shenzhen 518005, China; [email protected] (V.P.); [email protected] (P.E.L.) 3 Shenzhen Bay Laboratory, Shenzhen 518055, China 4 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore 5 Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University, Sector-125, Noida 201313, India; [email protected] * Correspondence: [email protected] (G.S.); [email protected] (A.K.P.) Received: 28 May 2020; Accepted: 19 June 2020; Published: 21 June 2020 Abstract: Triple-negative breast cancer (TNBC) is one of the most lethal forms of breast cancer (BC), with a significant disease burden worldwide. Chemoresistance and lack of targeted therapeutics are major hindrances to effective treatments in the clinic and are crucial causes of a worse prognosis and high rate of relapse/recurrence in patients diagnosed with TNBC. In the last decade, long non-coding RNAs (lncRNAs) have been found to perform a pivotal role in most cellular functions. The aberrant functional expression of lncRNAs plays an ever-increasing role in the progression of diverse malignancies, including TNBC. Therefore, lncRNAs have been recently studied as predictors and modifiers of chemoresistance.
    [Show full text]
  • A Common Analgesic Enhances the Anti-Tumour Activity of 5-Aza-2’- Deoxycytidine Through Induction of Oxidative Stress
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.31.017947; this version posted April 1, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. A common analgesic enhances the anti-tumour activity of 5-aza-2’- deoxycytidine through induction of oxidative stress Hannah J. Gleneadie1,10, Amy H. Baker1, Nikolaos Batis2, Jennifer Bryant2, Yao Jiang3, Samuel J.H. Clokie4, Hisham Mehanna2, Paloma Garcia5, Deena M.A. Gendoo6, Sally Roberts5, Alfredo A. Molinolo7, J. Silvio Gutkind8, Ben A. Scheven1, Paul R. Cooper1, Farhat L. Khanim9 and Malgorzata Wiench1, 5,*. 1School of Dentistry, Institute of Clinical Studies, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B5 7EG, UK; 2Institute of Head and Neck Studies and Education (InHANSE), The University of Birmingham, Birmingham, B15 2TT, UK; 3School of Biosciences, The University of Birmingham, Birmingham, B15 2TT, UK; 4West Midlands Regional Genetics Laboratory, Birmingham Women’s and Children’s Hospital, Birmingham, B15 2TG, UK; 5Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B15 2TT, UK; 6Centre for Computational Biology, Institute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham, B15 2TT, UK; 7Moores Cancer Center and Department of Pathology, University of California San Diego, La Jolla, CA 92093, USA; 8Department of Pharmacology and Moores Cancer
    [Show full text]
  • Effects of Circadian Clock Genes and Health-Related
    RESEARCH ARTICLE Effects of circadian clock genes and health- related behavior on metabolic syndrome in a Taiwanese population: Evidence from association and interaction analysis Eugene Lin1,2,3*, Po-Hsiu Kuo4, Yu-Li Liu5, Albert C. Yang6,7, Chung-Feng Kao8, Shih- Jen Tsai6,7* 1 Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, 2 Vita Genomics, Inc., Taipei, Taiwan, 3 TickleFish Systems Corporation, Seattle, Western Australia, United States of America, a1111111111 4 Department of Public Health, Institute of Epidemiology and Preventive Medicine, National Taiwan a1111111111 University, Taipei, Taiwan, 5 Center for Neuropsychiatric Research, National Health Research Institutes, a1111111111 Miaoli County, Taiwan, 6 Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan, 7 Division of Psychiatry, National Yang-Ming University, Taipei, Taiwan, 8 Department of Agronomy, College a1111111111 of Agriculture & Natural Resources, National Chung Hsing University, Taichung, Taiwan a1111111111 * [email protected] (EL); [email protected] (SJT) Abstract OPEN ACCESS Citation: Lin E, Kuo P-H, Liu Y-L, Yang AC, Kao C- Increased risk of developing metabolic syndrome (MetS) has been associated with the cir- F, Tsai S-J (2017) Effects of circadian clock genes cadian clock genes. In this study, we assessed whether 29 circadian clock-related genes and health-related behavior on metabolic (including ADCYAP1, ARNTL, ARNTL2, BHLHE40, CLOCK, CRY1, CRY2, CSNK1D, syndrome in a Taiwanese population: Evidence from association and interaction analysis. PLoS CSNK1E, GSK3B, HCRTR2, KLF10, NFIL3, NPAS2, NR1D1, NR1D2, PER1, PER2, ONE 12(3): e0173861. https://doi.org/10.1371/ PER3, REV1, RORA, RORB, RORC, SENP3, SERPINE1, TIMELESS, TIPIN, VIP, and journal.pone.0173861 VIPR2) are associated with MetS and its individual components independently and/or Editor: Etienne Challet, CNRS, University of through complex interactions in a Taiwanese population.
    [Show full text]
  • Transcriptome Signature of the Lactation Process in a Fat-Tailed Sheep Identifes with Integrative Approach of RNA-Seq and Supervised Machine Learning Models
    Transcriptome signature of the lactation process in a fat-tailed sheep identies with integrative approach of RNA-Seq and Supervised Machine Learning models Mohammad Farhadian ( [email protected] ) University of Tabriz Seyed Abbas Rafat University of Tabriz Bahman Panahi ABRII Esmaeil Ebrahimie The University of Adelaide Research article Keywords: RNA-Seq, Milk, Sheep, Gene network, Gene Ontology Posted Date: July 18th, 2019 DOI: https://doi.org/10.21203/rs.2.11678/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/26 Abstract Background The mammary gland is a vital organ in mammalian that undergoes a substantial physiological transformation during the lactation process. Understanding the underlying molecular mechanism of the lactation process in the mammary gland is essential to unravel of the complexity of milk production process. This study was investigated the transcriptome proles of milk between two time point of lactation (day 20 as before peak time point (BF) and day 70 as after peak(AF)) in Iranian fat- tailed Ghezel sheep breed. Functional impacts of differentially expressed genes (DEGs) between two time points of the lactation were surveyed with Gene Ontology (GO) and Protein-Protein Interaction (PPI) network analysis. Moreover, to identify the transcriptome signature of the lactation process, supervised machine learning algorithms were integrated. Results Totally, 75 genes were dened as DEGs between BF and AF of lactation. Gene ontology of DEGs mainly enriched in metabolic process and oxidative phosphorylation. Moreover, PPI networks analysis highlighted the contribution of peroxisome proliferator- activated receptors (PPAR) signaling in the lactation process, oxidative phosphorylation and metabolic pathways.
    [Show full text]
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Cellular Senescence Bypass Screen Identifies New Putative Tumor
    Oncogene (2008) 27, 1961–1970 & 2008 Nature Publishing Group All rights reserved 0950-9232/08 $30.00 www.nature.com/onc ORIGINAL ARTICLE Cellular senescence bypass screen identifies new putative tumor suppressor genes JFM Leal1, J Fominaya1, A Casco´ n2, MV Guijarro1, C Blanco-Aparicio1, M Lleonart3, ME Castro1, SRamon y Cajal 3, M Robledo2, DH Beach4 and A Carnero1 1Experimental Therapeutics Programme, Centro Nacional de Investigaciones Oncolo´gicas (CNIO), Madrid, Spain; 2Molecular Pathology Programme, Centro Nacional de Investigaciones Oncolo´gicas (CNIO), Madrid, Spain; 3Departamento de Patologı´a, Hospital Vall d’Hebron, Barcelona, Spain and 4Institute for Cell and Molecular Sciences, Center for Cutaneous Biology, London, UK Senescence is a mechanism that limits cellular lifespan and Introduction constitutes a barrier against cellular immortalization. To identify new senescence regulatory genes that might play a Replicative senescence is characterized by a progressive role in tumorigenesis, we have designed and performed a loss of proliferative potential with the increase of popu- large-scale antisense-based genetic screen in primary lation doublings, resulting in a permanent and irrever- mouse embryo fibroblasts (MEFs). Out of this screen, sible cell-cycle arrest. Although the process of senescence we have identified five different genes through which loss occurs both in vitro and in vivo (Dimri et al., 1995; of function partially bypasses senescence. These genes Schmitt et al., 2002; Shay and Roninson, 2004; Braig belong to very different biochemical families: csn2 et al., 2005; Collado et al., 2005; Michaloglou et al., (component of the Cop9 signalosome), aldose reductase 2005), the transition to the senescent phenotype is (a metabolic enzyme) and brf1 (subunit of the RNA commonly studied in culture where a cell population polymerase II complex), S-adenosyl homocysteine hydro- can be grown and monitored.
    [Show full text]
  • Thyroid Hormone Negatively Regulates Tumorigenesis Through Suppression of BC200
    25 12 Endocrine-Related Y-H Lin et al. BC200 is an oncogenic driver 25:12 967–979 Cancer in HCC RESEARCH Thyroid hormone negatively regulates tumorigenesis through suppression of BC200 Yang-Hsiang Lin1,2, Meng-Han Wu1, Ya-Hui Huang2, Chau-Ting Yeh2, Hsiang-Cheng Chi1,3, Chung-Ying Tsai4, Wen-Yu Chuang5, Chia-Jung Yu6,7,8,9, I-Hsiao Chung1, Ching-Ying Chen1 and Kwang-Huei Lin1,2,7,10 1Department of Biochemistry, College of Medicine, Chang Gung University, Taoyuan, Taiwan 2Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 3Radiation Biology Research Center, Institute for Radiological Research, Chang Gung University/Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 4Kidney Research Center and Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, Taiwan 5Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan 6Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan 7Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan 8Department of Cell and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan 9Department of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan 10Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, Taiwan Correspondence should be addressed to K-H Lin: [email protected] Abstract Thyroid hormone (T3) and its receptor (TR) are involved in cancer progression. While Key Words deregulation of long non-coding RNA (lncRNA) expression has been detected in f thyroid hormone many tumor types, the mechanisms underlying specific involvement of lncRNAs in f non-coding RNA tumorigenicity remain unclear.
    [Show full text]